Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Prednisolone absorption in coeliac disease.

M E Pickup, F Farah, J R Lowe

European Journal of Drug Metabolism and Pharmacokinetics

|January 1, 1979

Summary

Coeliac disease does not significantly affect how the body processes prednisolone. This study found no major differences in prednisolone absorption or elimination in coeliac patients compared to healthy individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bone Sialoprotein Is Critical for Alveolar Bone Healing in Mice.

Journal of dental research·2022

Same author

Severe Headache from Carious Teeth.

Atlanta medical and surgical journal·2022

Same author

Nitrate of Silver in Toothache.

Atlanta medical and surgical journal·2022

Same author

Effects of Decayed Teeth.

Atlanta medical and surgical journal·2022

Same author

Prevalence and temporal trends of anemia in patients with heart failure.

QJM : monthly journal of the Association of Physicians·2021

Same author

Dental defects in the primary dentition associated with hypophosphatasia from biallelic ALPL mutations.

Bone·2020

Area of Science:

Pharmacokinetics
Gastroenterology
Clinical Pharmacology

Background:

Coeliac disease is an autoimmune disorder affecting the small intestine.
Prednisolone is a corticosteroid commonly used to manage inflammatory conditions.
Understanding drug disposition in coeliac disease is crucial for effective treatment.

Purpose of the Study:

To investigate the pharmacokinetic disposition of prednisolone in patients with coeliac disease.
To compare prednisolone absorption and elimination in untreated coeliac patients, treated coeliac patients, and healthy controls.

Main Methods:

Oral administration of 10 mg prednisolone to three groups: untreated coeliac disease patients, treated coeliac disease patients, and normal subjects.
Analysis of pharmacokinetic parameters including peak plasma levels, time to peak, area under the curve, plasma half-life, and 24-hour urinary recovery.
Statistical comparison of these parameters across the three study groups.

Main Results:

No significant differences were observed in peak prednisolone levels, time to peak, area under the concentration-time curve, or plasma half-life among the three groups.
24-hour urinary recovery of prednisolone also showed no significant variations between untreated coeliac patients, treated coeliac patients, and normal subjects.
Considerable inter-individual variability in prednisolone pharmacokinetics was noted within each group.

Conclusions:

The presence of coeliac disease, whether treated or untreated, does not significantly alter the pharmacokinetic disposition of orally administered prednisolone.
Prednisolone absorption and elimination appear unaffected by coeliac disease, suggesting standard dosing can be used.
Further research may explore the reasons for observed inter-individual variability in prednisolone pharmacokinetics.

Related Experiment Videos